The Apex Times
Above the Noise
Business Wire
BusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessYahoo Finance flags a single metric as Disney stock remains under pressure this OctoberThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessYahoo Finance flags a single metric as Disney stock remains under pressure this OctoberThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessYahoo Finance flags a single metric as Disney stock remains under pressure this OctoberThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessYahoo Finance flags a single metric as Disney stock remains under pressure this OctoberThe Apex Times
Back to front
Eli Lilly rumored to be nearing a deal for psychedelic drug developer AtaiBeckley, shares jump
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 16, 7:25 AM EDT

Eli Lilly rumored to be nearing a deal for psychedelic drug developer AtaiBeckley, shares jump

AtaiBeckley surged about 50% ahead of the open after a market report said Eli Lilly is in talks to buy the psychedelic-focused company at a premium. Neither company confirmed the negotiations in the posting that circulated to markets.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Shares of AtaiBeckley rose roughly 50% ahead of the market open Thursday after a report circulated that Eli Lilly is nearing a deal to buy the psychedelic drug developer.

The move appeared tied to takeover-talk speculation rather than any new company-specific clinical or regulatory update disclosed in the reporting that reached investors that morning.

According to the report, the transaction being negotiated would be at a premium, implying that Eli Lilly would pay more than AtaiBeckley’s prevailing market value to secure the acquisition.

For Eli Lilly, a potential deal in the psychedelic space would represent a bet on a therapeutic area that has attracted major interest globally, but one where development timelines and regulatory pathways can be uncertain.

For AtaiBeckley, an acquisition by a large pharmaceutical company could potentially change the company’s funding and development posture, since it would shift the burden of late-stage investment from a smaller biotech to a well-capitalized drugmaker, if talks advance.

The company did not disclose in the circulated posting any binding terms, deal structure, or timing details, and the report did not identify whether the negotiations are exclusive or subject to conditions such as due diligence or regulatory approvals.

Both sides also did not provide additional comment in the market-facing article, leaving investors to assess the likelihood of a completed transaction based largely on the premium-and-nearing-deal framing rather than confirmed documentation.

Until more information is published by either company, the only clearly attributable fact for traders is the market reaction to the takeover report and the direction of the speculation: that Eli Lilly is in advanced discussions to acquire AtaiBeckley.

Why It Matters

  • If confirmed, an Eli Lilly acquisition of a psychedelic-focused developer would announcement continued corporate interest in fast-growing but still early-stage therapeutic modalities.
  • A premium offer can lift biotech valuations quickly, but it can also unwind if talks fail or if regulatory hurdles emerge.
  • For Eli Lilly, the move would broaden the company’s portfolio beyond traditional small-molecule and biologics pipelines into a different category of drug development.
  • For investors, the primary near-term variable would be whether either company provides a formal statement, rather than any new clinical data.

Sources

Key Facts

  • AtaiBeckley shares were reported to be up about 50% ahead of Thursday’s open following a takeover report.
  • The report said Eli Lilly is nearing a deal to buy AtaiBeckley.
  • The report characterized the negotiations as involving a premium to AtaiBeckley’s market value.
  • No details beyond the existence of talks and the premium characterization were included in the market posting.
  • The reporting did not indicate deal timing, exclusivity, or completion conditions.

Healthcare Related

Eli Lilly rumored to be nearing a deal for psychedelic drug developer AtaiBeckley, shares jump | The Apex Times